Ser164
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser164  -  NPM-ALK (human)

Site Information
CFAGKTSsISDLKEV   GenPept
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 27275103

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry ( 1 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
lymphoma ( 1 ) , anaplastic large cell lymphoma ( 1 ) , T cell lymphoma ( 1 )
Relevant cell line - cell type - tissue:
293GP (epithelial) ( 1 ) , Karpas-299 (T lymphocyte) ( 1 ) , SU-DHL1 (T lymphocyte) ( 1 ) , SUP-M2 (T lymphocyte) ( 1 )

Upstream Regulation
Treatments:
D4476 ( 1 ) , GSK-3_inhibitor_IX ( 1 )

Downstream Regulation
Effects of modification on NPM-ALK:
phosphorylation ( 1 )
Effects of modification on biological processes:
carcinogenesis, altered ( 1 ) , cell growth, altered ( 1 )

References 

1

Wang P, et al. (2011) Serine phosphorylation of NPM-ALK, which is dependent on the auto-activation of the kinase activation loop, contributes to its oncogenic potential. Carcinogenesis 32, 146-53
21045017   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.